Research ArticleAccepted Article
Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, & Medication Change
Taysir G Mahmoud, Jie Huang, Michelle Frits, Christine Iannaccone, Vivian Bykerk, Clifton O. Bingham III, Michael Weinblatt and Nancy A Shadick
The Journal of Rheumatology June 2019, jrheum.181160; DOI: https://doi.org/10.3899/jrheum.181160
Taysir G Mahmoud
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud@bwh.harvard.edu
Jie Huang
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud@bwh.harvard.edu
Michelle Frits
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud@bwh.harvard.edu
Christine Iannaccone
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud@bwh.harvard.edu
Vivian Bykerk
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud@bwh.harvard.edu
Clifton O. Bingham III
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud@bwh.harvard.edu
Michael Weinblatt
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud@bwh.harvard.edu
Nancy A Shadick
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA, 02115, United States of America; Division of Rheumatology, Hospital for Special Surgery, New York, NY, 10021, United States of America; Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD, 21205, United States of America Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Additionally, the BRASS registry is funded by Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Regeneron, and Sanofi. BRASS Clinical Trial Registration Number: Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Address correspondence to Taysir Mahmoud Division of Rheumatology, Immunology, & Allergy, Brigham & Women’s Hospital 60 Fenwood Road, Boston, MA, 02115, United States of America Telephone: 617-732-8964 | Fax: 617-713-3030 | Email: tmahmoud@bwh.harvard.edu
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, & Medication Change
Taysir G Mahmoud, Jie Huang, Michelle Frits, Christine Iannaccone, Vivian Bykerk, Clifton O. Bingham , Michael Weinblatt, Nancy A Shadick
The Journal of Rheumatology Jun 2019, jrheum.181160; DOI: 10.3899/jrheum.181160
Accepted manuscript
Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, & Medication Change
Taysir G Mahmoud, Jie Huang, Michelle Frits, Christine Iannaccone, Vivian Bykerk, Clifton O. Bingham , Michael Weinblatt, Nancy A Shadick
The Journal of Rheumatology Jun 2019, jrheum.181160; DOI: 10.3899/jrheum.181160